MiMedx Group, Inc
(NASDAQ:MDXG)

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts. The company's patented and proprietary processing method employs aseptic pr...

Website: https://mimedx.com/

Founded: 2008

CEO: Tim Wright

Sector: Manufacturing

Industry: Small Arms, Ordnance, and Ordnance Accessories Manufacturing

Share this website to your friends

• Market Cap:

• Exchange:

• Shs Outstanding:

• Employees:

• Beta:

• Return on Equity (ROE) ttm:

• Return on Assets (ROA) ttm:

• EPS ttm:

• Book value per Share:

• Cash per Share:

• Current ast per Share:

• P/E ttm:

• P/E forward:

• P/E ttm high:

• P/E ttm low:

• P/S ttm:

• P/B ttm:

• P/FCF ttm:

• PEG ratio:

• Cash Ratio ttm:

• Quick Ratio ttm:

• Current Ratio ttm:

• Gross Mgn ttm:

• EBITDA Mgn ttm:

• Operating Mgn ttm:

• Net Income Mgn ttm:

• Trailing Div yield:

• Forward Div yield:

• Payout Ratio ttm:

• Ex-Dividend date:

• Target Price High:

• Target Price Low:

• Target Price Mean:

• Number of Analysts:

• Debt Ratio ttm:

• Debt to Equity ttm:

• Total Net Debt:

At a glance:

Bull Thesis:

Bear Thesis:

Main Competitors:

Moat:

Income Statements:

Quarterly

Annual

Unit: USD	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-09-30	2009-06-30	2009-03-31	2008-12-31	2008-09-30	2008-06-30	2008-03-31

net sales	118,095,000	113,725,000	98,605,000	88,205,000	92,907,000	84,057,000	87,207,000	84,709,000	86,832,000	81,712,000	81,257,000	71,676,000	74,375,000	67,689,000	66,883,000	58,894,000	67,409,000	63,074,000	68,165,000	59,967,000	68,548,000	64,303,000	53,647,000	61,736,000	76,400,000	88,863,000	67,437,000	66,555,000	125,519,000	84,573,000	76,412,000	72,607,000	69,876,000	64,429,000	57,342,000	53,367,000	51,835,000	49,015,000	45,679,000	40,767,000	39,572,852	33,517,762	25,573,198	19,559,188	17,993,791	16,115,708	13,514,743	11,556,493	10,509,663	7,954,046	4,884,256	3,705,808	2,635,466	2,152,094	1,929,399	1,043,487	-801	108,027	322,075	114,855
yoy	27.11%	35.30%	13.07%	4.13%	7.00%	2.87%	7.32%	18.18%	16.75%	20.72%	21.49%	21.70%	10.33%	7.32%	-1.88%	-1.79%	-1.66%	-1.91%	27.06%	-2.87%	-10.28%	-27.64%	-20.45%	-7.24%	-39.13%	5.07%	-11.75%	-8.34%	79.63%	31.27%	33.26%	36.05%	34.80%	31.45%	25.53%	30.91%	30.99%	46.24%	78.62%	108.43%	119.93%	107.98%	89.22%	69.25%	71.21%	102.61%	176.70%	211.85%	298.78%	269.60%	153.15%	255.14%	-329121.97%	1892.18%	499.05%	808.53%
qoq	3.84%	15.33%	11.79%	-5.06%	10.53%	-3.61%	2.95%	-2.44%	6.27%	0.56%	13.37%	-3.63%	9.88%	1.21%	13.57%	-12.63%	6.87%	-7.47%	13.67%	-12.52%	6.60%	19.86%	-13.10%	-19.19%	-14.02%	31.77%	1.33%	-46.98%	48.41%	10.68%	5.24%	3.91%	8.45%	12.36%	7.45%	2.96%	5.75%	7.30%	12.05%	3.02%	18.07%	31.07%	30.75%	8.70%	11.65%	19.25%	16.95%	9.96%	32.13%	62.85%	31.80%	40.61%	22.46%	11.54%	84.90%	-130373.03%	-100.74%	-66.46%	180.42%
cost of sales	19,055,000	18,719,000	18,681,000	16,558,000	16,909,000	15,322,000	14,855,000	12,987,000	13,842,000	14,790,000	13,583,000	12,419,000	14,369,000	12,188,000	11,823,000	9,936,000	10,753,000	10,129,000	12,760,000	9,641,000	10,817,000	10,289,000	8,198,000	10,025,000	12,709,000	13,205,000	9,749,000	7,418,000	9,414,000	9,599,000	8,631,000	8,743,000	9,069,000	7,997,000	7,394,000	7,946,000	4,985,000	4,979,000	5,089,000	5,148,000	3,599,752	3,348,005	2,739,967	2,977,275	3,111,174	2,113,438	2,198,482	1,905,020
gross profit	99,040,000	95,006,000	79,924,000	71,647,000	75,998,000	68,735,000	72,352,000	71,722,000	72,990,000	66,922,000	67,674,000	59,257,000	60,006,000	55,501,000	55,060,000	48,958,000	56,656,000	52,945,000	55,405,000	50,326,000	57,731,000	54,014,000	45,449,000	51,711,000
yoy	30.32%	38.22%	10.47%	-0.10%	4.12%	2.71%	6.91%	21.04%	21.64%	20.58%	22.91%	21.04%	5.91%	4.83%	-0.62%	-2.72%	-1.86%	-1.98%	21.91%	-2.68%
qoq	4.25%	18.87%	11.55%	-5.73%	10.57%	-5.00%	0.88%	-1.74%	9.07%	-1.11%	14.20%	-1.25%	8.12%	0.80%	12.46%	-13.59%	7.01%	-4.44%	10.09%	-12.83%	6.88%	18.85%	-12.11%
gross margin %	83.86%	83.54%	81.05%	81.23%	81.80%	81.77%	82.97%	84.67%	84.06%	81.90%	83.28%	82.67%	80.68%	81.99%	82.32%	83.13%	84.05%	83.94%	81.28%	83.92%	84.22%	84.00%	84.72%	83.76%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%
operating expenses:
selling, general and administrative	73,073,000	69,001,000	64,151,000	59,969,000	61,043,000	53,516,000	55,401,000	55,129,000	54,351,000	52,571,000	51,925,000	52,279,000	49,951,000	53,475,000	55,793,000	49,570,000	53,068,000	46,289,000	53,599,000	45,404,000	48,706,000	48,046,000	37,329,000	46,942,000	45,444,000	51,258,000	50,641,000	50,862,000
research and development	4,761,000	3,703,000	3,303,000	3,328,000	3,571,000	2,918,000	3,012,000	2,841,000	-5,503,000	3,175,000	8,497,000	6,496,000	5,400,000	5,953,000	5,512,000	5,964,000	4,574,000	4,368,000	4,063,000	4,339,000	3,434,000	3,372,000	2,259,000	2,650,000	2,719,000	2,691,000	2,828,000	2,902,000
investigation, restatement and related					43,000	649,000	-9,701,000	311,000	524,000	-38,000	1,017,000	3,673,000	3,406,000	3,001,000	3,218,000	2,552,000	-4,513,000	3,170,000	-2,062,000	7,196,000	20,400,000	12,027,000	11,446,000	15,592,000	20,130,000	7,242,000	21,025,000	18,107,000
amortization of intangible assets	129,000	112,000	100,000	99,000	193,000	192,000	190,000	189,000	192,000	190,000	191,000	190,000	182,000	175,000	173,000	172,000	173,000	193,000	215,000	239,000	255,000	276,000	271,000	271,000	270,000	269,000	267,000	233,000	-417,000	418,000	507,000	526,000	238,000	631,000	447,000	810,000	234,000	234,000	233,000	233,000	232,632	232,079	231,959	231,331	264,162	259,575	267,638	262,596
impairment of intangible assets					94,000	298,000		54,000																				446,000																						1,798,495
operating income	21,077,000	22,190,000	12,370,000	8,251,000	11,054,000	11,162,000	23,450,000	13,198,000	26,890,000	10,816,000	2,788,000	-3,381,000	1,067,000	-7,103,000	-9,636,000	-9,300,000	3,301,000	-1,075,000	-410,000	-6,852,000	-16,091,000	-9,707,000	-5,856,000	-13,744,000	-4,872,000	14,198,000	-17,073,000	-13,413,000	-26,165,000	8,842,000	7,213,000	6,185,000	8,715,000	4,703,000	3,561,000	1,467,000	7,751,000	6,714,000	5,652,000	4,247,000	4,651,885	3,730,893	-391,763	-891,015	-306,749.5	-255,891	-744,217	-226,890
yoy	90.67%	98.80%	-47.25%	-37.48%	-58.89%	3.20%	741.10%	-490.36%	2420.15%	-252.27%	-128.93%	-63.65%	-67.68%	560.74%	2250.24%	35.73%	-120.51%	-88.93%	-93.00%	-50.15%	230.28%	-168.37%	-65.70%	2.47%	-81.38%	60.57%	-336.70%	-316.86%	-400.23%	88.01%	102.56%	321.61%	12.44%	-29.95%	-37.00%	-65.46%	66.62%	79.96%	-1542.71%	-576.65%	-1616.51%	-1558.00%	-47.36%	292.71%
qoq	-5.02%	79.39%	49.92%	-25.36%	-0.97%	-52.40%	77.68%	-50.92%	148.61%	287.95%	-182.46%	-416.87%	-115.02%	-26.29%	3.61%	-381.73%	-407.07%	162.20%	-94.02%	-57.42%	65.77%	65.76%	-57.39%	182.10%	-134.31%	-183.16%	27.29%	-48.74%	-395.92%	22.58%	16.62%	-29.03%	85.31%	32.07%	142.74%	-81.07%	15.45%	18.79%	33.08%	-8.70%	24.69%	-1052.33%	-56.03%	190.47%	19.88%	-65.62%	228.01%
operating margin %	17.85%	19.51%	12.55%	9.35%	11.90%	13.28%	26.89%	15.58%	30.97%	13.24%	3.43%	-4.72%	1.43%	-10.49%	-14.41%	-15.79%	4.90%	-1.70%	-0.60%	-11.43%	-23.47%	-15.10%	-10.92%	-22.26%	-6.38%	15.98%	-25.32%	-20.15%	-20.85%	10.45%	9.44%	8.52%	12.47%	7.30%	6.21%	2.75%	14.95%	13.70%	12.37%	10.42%	11.76%	11.13%	-1.53%	-4.56%	-1.70%	-1.59%	-5.51%	-1.96%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%
other expense	-186,000	-126,000	-101,000	-145,000	-208,000	-21,000	-237,000		16,000	-11,000	-32,000		-3,000						-3,000									-29,000
interest income	904,000	785,000	738,000	506,000	-352,250	278,000	3,000																	-2,387,000	-2,395,000	-2,255,000	-269,000	211,000					-63,500	-87,000	-111,000		-4,500	-5,000	1,000														-141,319	-113,366	-87,070
income from continuing operations before income tax	21,795,000	22,849,000	13,007,000	8,612,000				11,409,000
income tax provision	-2,770,000	-6,101,000	-3,389,000	-1,589,000																													-746,000	-1,295,000	-1,475,000	-214,000	5,695,000	-158,000	-223,000	-146,000	-809,938	-22,062	10,033	-10,033	-24,243.75	-46,700		-50,275
net income from continuing operations	15,191,000	16,748,000	9,618,000	7,023,000	7,438,000	7,878,000	17,621,000	9,061,000
income from discontinued operations, net of tax						217,000	4,000	200,000
net income	15,191,000	16,748,000	9,618,000	7,023,000	7,438,000	8,095,000	17,625,000	9,261,000	53,477,000	8,534,000	1,200,000	-4,983,000	-414,000	-8,426,000	-10,868,000	-10,489,000	2,215,000	-2,339,000	-1,779,000	-8,382,000	-16,580,000	-19,417,000	-8,466,000	-4,821,000	-7,476,000	12,379,000	-17,210,000	-13,273,000	-59,832,000	17,457,000	8,069,000	4,327,000	5,481,000	3,321,000	1,975,000	1,197,000	13,378,000	6,551,000	5,430,000	4,087,000	3,832,526	3,699,705	-390,159	-922,072	-1,426,938	-307,118	-757,389	-1,620,408	-1,605,284	-4,219,372	-744,069	-1,093,652	-2,577,195	-1,765,723	-2,503,505	-3,347,562	-2,726,657	-2,854,442	-2,696,569	-3,142,085	-4,486,576	-1,597,543	-2,871,984	-2,309,055	-3,586,350	-3,151,882
yoy	104.24%	106.89%	-45.43%	-24.17%	-86.09%	-5.14%	1368.75%	-285.85%	-13017.15%	-201.28%	-111.04%	-52.49%	-118.69%	260.24%	510.91%	25.14%	-113.36%	-87.95%	-78.99%	73.86%	121.78%	-256.85%	-50.81%	-63.68%	-87.51%	-29.09%	-313.29%	-406.75%	-1191.63%	425.65%	308.56%	261.49%	-59.03%	-49.31%	-63.63%	-70.71%	249.06%	77.07%	-1491.74%	-543.24%	-368.58%	-1304.65%	-48.49%	-43.10%	-11.11%	-92.72%	1.79%	48.16%	-37.71%	138.96%	-70.28%	-67.33%	-5.48%	-38.14%	-7.16%	6.54%	-39.23%	78.68%	-6.11%	36.08%	25.10%	-49.31%
qoq	-9.30%	74.13%	36.95%	-5.58%	-8.12%	-54.07%	90.31%	-82.68%	526.63%	611.17%	-124.08%	1103.62%	-95.09%	-22.47%	3.61%	-573.54%	-194.70%	31.48%	-78.78%	-49.45%	-14.61%	129.35%	75.61%	-35.51%	-160.39%	-171.93%	29.66%	-77.82%	-442.74%	116.35%	86.48%	-21.05%	65.04%	68.15%	65.00%	-91.05%	104.21%	20.64%	32.86%	6.64%	3.59%	-1048.26%	-57.69%	-35.38%	364.62%	-59.45%	-53.26%	0.94%	-61.95%	467.07%	-31.96%	-57.56%	45.96%	-29.47%	-25.21%	22.77%	-4.48%	5.85%	-14.18%	-29.97%	180.84%	-44.37%	24.38%	-35.62%	13.78%
net income margin %	12.86%	14.73%	9.75%	7.96%	8.01%	9.63%	20.21%	10.93%	61.59%	10.44%	1.48%	-6.95%	-0.56%	-12.45%	-16.25%	-17.81%	3.29%	-3.71%	-2.61%	-13.98%	-24.19%	-30.20%	-15.78%	-7.81%	-9.79%	13.93%	-25.52%	-19.94%	-47.67%	20.64%	10.56%	5.96%	7.84%	5.15%	3.44%	2.24%	25.81%	13.37%	11.89%	10.03%	9.68%	11.04%	-1.53%	-4.71%	-7.93%	-1.91%	-5.60%	-14.02%	-15.27%	-53.05%	-15.23%	-29.51%	-97.79%	-82.05%	-129.76%	-320.81%	340406.62%	-2642.34%	-837.25%	-2735.70%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%
basic net income per common share:
continuing operations	100	110	70	50	50	50	120	60
discontinued operations
basic net income per common share	57.5	110	70	50	60	50	120	60
diluted net income per common share:
diluted net income per common share	55	110	60	50	57.5	50	120	60
weighted-average common shares outstanding - basic	147,793,069,000	148,035,283,000	147,761,332,000	147,272,324,000	146,979,354,000	146,958,986,000	147,326,273,000	146,404,587,000	116,495,810,000	116,298,146,000	115,866,371,000	114,398,813,000	112,909,266,000	113,448,251,000	112,867,912,000	111,615,839,000	110,353,406,000	110,717,073,000	110,276,636,000	109,401,383,000	108,257,112,000
weighted-average common shares outstanding - diluted	149,724,507,000	149,713,653,000	149,317,281,000	149,677,452,000	149,049,197,000	148,373,631,000	148,897,920,000	150,028,107,000	145,962,462,000	119,327,709,000	115,866,371,000	114,398,813,000	112,909,266,000	113,448,251,000	112,867,912,000	111,615,839,000	110,353,406,000	110,717,073,000	110,276,636,000	109,401,383,000	108,257,112,000
continuing operations:				50
discontinued operations:
income from continuing operations before income tax provision					11,249,000	11,419,000	23,216,000
income tax provision from continuing operations					-2,871,250	-3,541,000
net income available to common stockholders from continuing operations					7,438,000	7,878,000	17,621,000
income tax provision benefit from continuing operations							-5,595,000
interest expense								-1,690,000	-1,593,000	-1,680,000	-1,630,000	-1,553,000	-1,450,000	-1,270,000	-1,170,000	-1,126,000	-1,174,000	-963,000	-1,371,000	-1,472,000	-1,608,250	-1,472,000	-2,574,000						-84,250	-43,000	-149,000	-145,000								-14,000	-9,421	-9,126	-8,429	-21,024	-8,125.75	-4,527	-13,172	-14,804	-141,696	-145,582	-153,804	-243,586				-91,216
other income								-99,000				2,000					-20,000				-1,000	1,000	-9,000	6,000	11,000	127,000	174,000																																				14,714.25	5,703	15,169	37,985
income tax expense from continuing operations								-2,348,000
net income from continuing operations available to common stockholders								9,061,000
restructuring									866,000	208,000	3,256,000
income before income tax provision									1,330,000	9,125,000	1,126,000										-10,985,750	-19,379,000			-7,256,000	12,070,000	-17,168,000	-13,231,000	-29,575,000	13,073,000	7,064,000	6,040,000	8,630,000	4,616,000	3,450,000	1,411,000	7,683,000	6,709,000	5,653,000	4,233,000	4,642,464	3,721,767	-400,192	-912,039	-646,985	-260,418	-757,389	-1,570,133
income tax provision expense									-142,250	-591,000		-51,000	-44,500	-53,000		-63,000
net income available to common shareholders									-108,250	6,761,000
net income per common share - basic										60															-70	120	-160	-120	-560	160	80	40	50	30	20	10	130	60	50	40	59.98	0.03
net income per common share - diluted										60															-70	110	-160	-120	-540	150	70	40	50	30	20	10	120	60	50	40	49.98	0.03
income tax provision benefit											74,000				-62,000		108,000	-301,000	5,000	-58,000	1,020,000	-38,000	-27,000	11,304,000	-220,000	309,000	-42,000	-42,000	-30,257,000	4,384,000		-1,713,000
net loss available to common shareholders											-528,000					-12,075,000	-4,259,750	-3,913,000
net loss per common share - basic												-60	-20	-90	-110	-110		-40	-30	-90	-170	-480	-80	-40
net loss per common share - diluted												-60	-20	-90	-110	-110		-40	-30	-90	-170	-480	-80	-40
loss before income tax provision												-4,932,000	-386,000	-8,373,000	-10,806,000	-10,426,000	2,107,000	-2,038,000	-1,784,000	-8,324,000			-8,439,000	-16,125,000
net loss available to common stockholders												-6,667,000	-2,110,000	-10,096,000	-12,496,000				-3,276,000	-9,850,000
loss on extinguishment of debt																						-8,201,000
net income available to common stockholders																					-16,317,250	-51,982,000
weighted-average shares outstanding - basic																						108,493,208,000	108,119,461,000	107,538,509,000	106,946,384,000	107,157,561,000	106,942,429,000	106,420,317,000	105,596,256,000	106,871,436,000	106,805,162,000	105,708,526,000	105,928,348,000	105,991,990,000	106,191,932,000	105,538,271,000	105,929,205,000	106,511,294,000	106,211,120,000	105,820,335,000	105,793,008,000	105,756,945
weighted-average shares outstanding - diluted																						108,493,208,000	108,119,461,000	107,538,509,000	106,946,384,000	109,590,008,000	106,942,429,000	106,420,317,000	105,596,256,000	117,501,925,000	117,285,865,000	113,730,591,000	112,441,709,000	112,361,179,000	112,148,415,000	112,039,860,000	113,628,482,000	114,556,036,000	114,186,329,000	113,638,551,000	113,295,504,000	112,814,658
impairment of intangible asset																									111,500
gross margin																									48,120,750	75,658,000	57,688,000	59,137,000	51,655,000	74,974,000	67,781,000	63,864,000	60,807,000	56,432,000	49,948,000	45,421,000	46,850,000	44,036,000	40,590,000	35,619,000	35,973,100	30,169,757	22,833,231	16,581,913	14,882,617	14,002,270	11,316,261	9,651,473
research and development expenses																													3,607,500	5,481,000	4,747,000	4,202,000	3,456,000	2,919,000	3,168,000	2,496,000	2,341,000	2,187,000	2,054,000	1,831,000	1,845,847	2,014,306	1,799,803	1,390,044	1,384,872	1,287,361	924,468	1,246,757	1,135,699	838,690	503,086	407,072	607,125	485,236	662,487	847,903	585,288	842,929	752,711	572,404	949,281	773,517	957,084	886,270	1,225,809	953,546
selling, general and administrative expenses																													42,124,500	60,233,000	55,314,000	52,951,000	48,398,000	48,179,000	42,772,000	40,648,000	36,524,000	34,901,000	32,651,000	29,308,000	29,242,736	24,192,479	21,193,232	15,851,553	14,277,050	12,711,225	10,868,372	8,369,010	8,409,430	6,206,251	3,383,760	2,971,246	3,601,270	2,475,849	2,893,942	2,793,055	1,726,202	1,579,259	1,831,236	1,711,438
gain on divestiture																													1,068,500	4,274,000
income tax benefit																															1,005,000
interest (expense)																																				-56,000
amortization of debt discount																																													-332,109.75			-1,328,439
net income per common share - basic and diluted																																												-0.01	-0.01		-0.01	-0.02
weighted-average shares outstanding - basic and diluted																																											105,757,178	105,358,694	96,285,504	96,914,856	95,988,100	93,128,466
fair value adjustment of earn-out liability																																																	247,050	1,320,000
revenues:
operating costs and expenses:
cost of products sold																																																	1,689,261	1,425,336	1,114,926	958,855	862,947	843,366	789,405	658,875	364,853	539,697	435,925	379,588
income from operations																																																	-971,777	-3,634,726	-117,516	-631,365	-2,435,876	-1,652,357	-2,416,435	-3,256,346	-2,432,425	-2,853,858	-2,697,797	-2,548,575	-2,408,627	-2,107,833	-2,872,678	-2,314,758	-3,601,519	-3,189,867
financing expense associated with the debt discount recognized in connection with the senior secured promissory notes																																																	-305,572.5	-439,064	-472,749	-218,701
income before income taxes																																																	-1,605,284	-4,219,372	-744,069	-1,093,652	-2,577,195	-1,765,723	-2,503,505	-3,347,562	-2,726,657	-2,854,442	-2,696,569	-3,142,085	-4,486,576	-1,597,543	-2,871,984	-2,309,055	-3,586,350	-3,151,882
income taxes
net loss per common share
basic and diluted																																																	-0.02	-0.05	-0.01	-0.01	-0.03	-0.02	-0.03	-0.05	-0.04	-0.05	-0.04	-0.06		-0.04	-0.07	-0.08		-0.09
shares used in computing net loss per common share
basic and diluted																																																	-2,444,719	84,493,164	79,952,542	74,872,122	367,732	73,767,674	71,819,017	70,333,476	1,264,264	61,049,942	60,635,877	51,227,540	41,576,491	39,244,628	271,262	37,833,267	37,314,628	37,073,595
acquired in-process research and development
gain on sale of assets
financing expense associated with issuance of common stock for registration rights waivers
financing expense associated with warrants issued in connection with convertible promissory note
net interest income																																																									-148,216.5	-584	1,228	-593,510	-90,814	-54,548
change in fair value of investment, related party
accretion of redeemable common stock and common stock with registration rights to fair value																																																																-735,000
loss attributable to common shareholders																																																									-2,173,274	-2,854,442	-2,696,569	-3,142,085	-4,486,576		-2,871,984	-3,044,055	-5,010,173
general and administrative expenses																																																													1,459,346	1,334,316	1,915,594	1,428,488	2,375,710	2,236,321
other income:
gain on settlement of payables																																																													1,381	564,838
financing expense associated with registration rights/waivers																																																													-1,305,100
derivative expense																																																													-683,416
accretion of redeemable common stock to fair value																																																																	-1,423,823
loss attributable to common shareholders per common share
basic and diluted																																																													-0.11				-0.13

Balance Sheets:

Quarterly

Annual

Unit: USD	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-09-30	2009-06-30	2009-03-31	2008-12-31	2008-09-30	2008-06-30	2008-03-31

assets
current assets:
cash and cash equivalents	166,121,000	142,083,000	118,869,000	106,431,000	104,416,000	88,801,000	69,037,000	48,487,000	82,000,000		68,652,000	61,221,000	65,950,000	73,217,000	72,502,000	75,676,000	87,083,000	90,607,000	85,007,000	84,746,000	95,812,000	109,595,000	48,189,000	53,525,000	69,069,000	94,122,000	96,929,000	28,381,000	45,118,000	36,522,000	47,533,000	30,924,000	34,391,000	18,338,000	23,803,000	15,117,000	28,486,000	41,073,000	38,601,000	38,696,000	46,582,000	47,253,003	39,245,237	43,019,559	44,077,751	6,061,756	4,193,583	5,725,107	6,754,485	7,621,226	2,654,694	3,021,266	4,112,326	637,192	1,614,350	1,020,533	1,340,922	428,493	2,728,205	1,627,505	5,785	1,620,900	34,828	864,768	2,347,237	3,875,106	6,749,609
accounts receivable	75,707,000	78,186,000	69,228,000	62,288,000	55,828,000	54,030,000	52,798,000	57,016,000	53,871,000	49,005,000	48,963,000	44,694,000	43,084,000	40,830,000	37,661,000	37,674,000	40,353,000	36,536,000	37,243,000	35,420,000	35,423,000	33,042,000	30,097,000	31,932,000	32,327,000	21,389,000				59,581,000	60,738,000	66,846,000	67,151,000	63,427,000	54,861,000	53,882,000	53,755,000	46,778,000	39,448,000	31,001,000	26,672,000	23,304,472	20,499,578	18,966,543	16,092,836	13,706,524	11,761,874	9,821,503	7,653,561	6,170,124	3,946,333	2,853,552	1,891,919	1,501,565	1,212,594	503,185	162,376	259,476
inventory	25,340,000	26,502,000	24,890,000	24,070,000	23,807,000	24,249,000	25,056,000	24,454,000	21,021,000	19,068,000	16,815,000	14,657,000	13,183,000	13,976,000	13,382,000	13,170,000	11,389,000	11,196,000	10,137,000	11,582,000	10,361,000	11,023,000	10,565,000	9,247,000	9,104,000	12,034,000	14,952,000	16,428,000	15,986,000	10,419,000	15,033,000	16,050,000	17,814,000	18,313,000	17,207,000	17,967,000	7,460,000	5,653,000	3,860,000	4,248,000	5,133,000	4,738,690	4,229,291	3,639,094	3,880,776	4,533,062	4,220,284	3,956,339	3,022,784	1,802,335	961,939	795,516	712,602	609,139	561,917	570,643	111,554	117,821	95,328	68,276
other current assets	10,303,000	3,076,000	3,026,000	1,972,000	2,817,000	2,152,000	3,097,000	2,801,000	1,745,000	2,311,000	3,110,000	2,306,000	2,631,000	2,582,000	2,570,000	2,571,000	2,809,000	860,000	1,816,000	3,530,000	3,371,000	5,469,000	5,191,000	5,216,000	6,058,000	3,739,000	7,537,000	7,292,000	5,818,000	926,000	1,024,000	1,200,000	1,288,000
total current assets	277,471,000	254,095,000	220,876,000	200,112,000	191,886,000	172,139,000	154,018,000	138,853,000	164,261,000	154,502,000	141,223,000	131,702,000	134,198,000	136,040,000	131,009,000	135,907,000	148,523,000	141,902,000	147,691,000	149,964,000	160,617,000	171,474,000	107,592,000	115,888,000	123,245,000	134,022,000	122,500,000	57,187,000	74,049,000	114,110,000	132,546,000	121,898,000	126,538,000	106,290,000	101,841,000	95,240,000	96,310,000	102,745,000	91,806,000	82,286,000	85,677,000	77,264,455	66,299,641	67,904,192	65,388,771	25,845,711	21,527,689	20,689,366	18,088,791	16,140,400	7,855,189	7,047,829	6,881,511	3,002,590	3,623,053	2,343,073	1,705,798	929,459	3,326,079	1,983,290	186,039	1,669,982	117,781	873,089	2,406,072	3,942,683	6,938,862
property and equipment	4,713,000	5,003,000	5,390,000	5,773,000	5,944,000	6,451,000	6,822,000	7,340,000	6,974,000	7,094,000	7,261,000	7,562,000	7,856,000	7,912,000	8,328,000	8,759,000	9,165,000	9,856,000	10,273,000	11,044,000	11,437,000	10,255,000	10,820,000	11,833,000	12,328,000	13,180,000	14,672,000	16,377,000	17,424,000	13,264,000	14,419,000	13,763,000	13,786,000	13,757,000	13,049,000	12,123,000	9,475,000	8,376,000	7,184,000	6,440,000	5,447,000	5,052,209	4,680,476	4,288,743	4,086,106	3,761,633	2,990,746	1,153,667	1,071,625	999,866	948,720	805,817	869,411	916,871	741,387	825,569	756,956	861,189	946,704	954,260	1,159,250	1,268,065	1,375,896	1,470,489	1,548,131	1,582,818	1,452,436
deferred tax assets	19,596,000				28,306,000				40,777,000
goodwill	19,441,000	19,441,000	19,441,000	19,441,000	19,441,000	19,441,000	19,441,000	19,441,000	19,441,000	19,441,000	19,441,000	19,976,000	19,976,000	19,976,000	19,976,000	19,976,000	19,976,000	19,976,000	19,976,000	19,976,000	19,976,000	19,976,000	19,976,000	19,976,000	19,976,000	19,976,000	19,976,000	19,976,000	19,976,000	19,894,000	20,203,000	20,203,000	20,203,000	26,951,000	26,951,000	30,730,000	4,040,000	4,040,000	4,040,000	4,040,000	4,040,000	4,040,443	4,040,443	4,040,443	4,040,443	4,040,443	4,040,443	4,040,443	4,040,443	4,040,443	4,040,443	4,040,443	4,040,443	4,040,443	4,040,443	4,040,443	857,597	857,597	857,597	857,597	857,597	857,597	857,597	857,597	857,597	857,597	857,597
intangible assets	14,158,000	11,147,000	12,028,000	11,062,000	11,626,000	11,201,000	12,047,000	12,550,000	5,257,000	5,395,000	5,565,000	5,706,000	5,852,000	4,992,000	5,141,000	5,265,000	5,383,000	5,620,000	5,750,000	5,918,000	6,004,000	7,168,000	7,386,000	7,581,000	7,777,000	7,952,000	8,104,000	8,292,000	9,608,000																																		5,116,337				5,783,153
other assets	7,274,000	2,987,000	990,000	1,048,000	1,106,000	1,180,000	1,239,000	1,251,000	205,000	149,000	146,000	147,000	148,000	150,000	164,000	172,000	186,000	270,000	313,000	344,000	375,000	420,000	2,227,000	473,000	443,000	507,000	1,206,000	1,535,000	1,787,000	3,391,000								26,000	26,000	26,000
total assets	342,653,000	318,988,000	291,109,000	270,420,000	263,915,000	243,891,000	230,183,000	221,681,000	239,047,000	189,022,000	176,378,000	168,159,000	171,430,000	172,798,000	168,667,000	174,443,000	187,929,000	180,523,000	187,147,000	190,813,000	202,032,000	213,324,000	150,912,000	158,909,000	167,166,000	179,267,000	170,310,000	107,442,000	122,844,000	178,707,000	199,865,000	188,491,000	193,263,000	181,665,000	177,055,000	177,220,000	135,913,000	125,927,000	113,837,000	106,105,000	109,259,000	97,317,407	86,024,633	87,348,566	84,693,893	45,296,293	40,283,088	37,852,174	35,182,608	33,535,481	27,471,686	26,860,192	27,096,192	23,551,623	24,282,404	23,420,585	7,352,245	6,847,122	9,486,240	8,336,670	7,344,986	9,121,250	7,616,813	8,633,518	10,410,847	12,149,661	15,178,481
liabilities and stockholders’ equity
current liabilities:
current portion of long term debt	1,500,000	1,375,000	1,250,000	1,125,000	1,000,000	1,000,000	1,000,000	1,000,000															3,750,000	3,750,000	3,750,000	3,750,000	3,750,000
accounts payable	14,528,000	11,415,000	8,499,000	8,868,000	7,409,000	6,924,000	7,603,000	9,697,000	9,048,000	9,170,000	8,150,000	7,823,000	8,847,000	8,820,000	8,075,000	8,120,000	7,385,000	6,881,000	10,563,000	6,925,000	8,765,000	9,049,000	11,946,000	9,756,000	8,710,000	9,420,000	10,792,000	10,691,000	14,864,000	8,767,000	11,504,000	10,892,000	11,436,000	11,162,000	9,678,000	13,059,000	6,633,000	7,244,000	5,614,000	5,379,000	3,661,000	2,759,409	2,445,627	2,618,753	2,490,531	2,205,778	1,837,711	1,056,707	1,251,684
accrued compensation	31,065,000	27,650,000	22,025,000	18,744,000	23,667,000	20,170,000	17,645,000	17,913,000	22,353,000	23,159,000	21,602,000	18,212,000	21,852,000	24,090,000	17,280,000	17,102,000	23,595,000	19,475,000	21,257,000	16,153,000	18,467,000	18,528,000	20,784,000	17,116,000	21,302,000	21,076,000	19,210,000	15,523,000	23,024,000	15,092,000	14,719,000	11,602,000	12,365,000	10,812,000	10,245,000	9,394,000	15,034,000	12,997,000	9,661,000	8,720,000	11,523,000	9,448,245	6,154,401	5,413,595	5,588,811	4,560,380	2,974,709	3,518,769
accrued expenses	11,383,000	12,825,000	15,105,000	9,447,000	9,012,000	8,396,000	9,281,000	9,196,000	9,361,000	9,444,000	12,645,000	13,041,000	11,024,000	10,986,000	10,002,000	9,812,000	9,812,000	13,692,000	17,073,000	30,676,000	30,460,000	28,363,000	25,768,000	30,661,000	32,161,000	37,438,000	42,817,000	35,737,000	31,842,000	8,613,000	7,986,000	9,940,000	10,941,000	6,664,000	6,988,000	5,137,000	4,644,000	4,097,000	3,725,000	3,615,000	2,504,000	1,989,997	1,137,508	1,369,048	1,405,974	1,410,159	1,075,916	1,227,485	3,743,934
other current liabilities	5,790,000	4,417,000	3,411,000	4,435,000	3,086,000	2,591,000	2,070,000	4,071,000	3,894,000	1,854,000	2,063,000	1,794,000	1,834,000	1,962,000	1,781,000	1,557,000	1,565,000	1,698,000	1,678,000	1,657,000	1,470,000	1,357,000	1,415,000	2,416,000	1,399,000	1,683,000	1,534,000	2,396,000	1,817,000	358,000	550,000	587,000	1,482,000	3,298,000	1,985,000	1,252,000	466,000	14,000	461,000	746,000	716,000	251,578	175,247	192,522	122,551	155,077	252,343	167,600	75,154	78,634	69,981
total current liabilities	64,266,000	57,682,000	50,290,000	42,619,000	45,595,000	41,941,000	40,012,000	42,221,000	46,008,000	43,627,000	44,460,000	40,870,000	43,557,000	45,858,000	37,138,000	36,591,000	42,357,000	41,746,000	50,571,000	55,411,000	59,162,000	57,297,000	63,663,000	63,699,000	67,322,000	73,367,000	78,103,000	64,347,000	71,547,000	35,159,000	51,511,000	49,600,000	50,732,000	41,578,000	38,538,000	28,842,000	26,777,000	24,352,000	19,461,000	18,460,000	18,404,000	14,449,229	9,912,783	9,593,918	9,607,867	8,331,394	6,140,679	5,970,561	5,070,772	10,548,110	8,239,835	6,796,440	7,917,267	6,827,561	5,564,192	2,698,032	1,251,717	1,143,645	1,261,289	928,050	1,911,462	1,106,925	1,699,337	1,190,689	1,532,054	841,898	948,478
long term debt	16,467,000	16,839,000	17,211,000	17,533,000	17,830,000	18,018,000	18,249,000	18,453,000	48,099,000	48,966,000	48,838,000	48,714,000	48,594,000	48,475,000	48,356,000	48,239,000	48,127,000	48,015,000	47,905,000	47,799,000	47,697,000	47,627,000	61,472,000	61,637,000	61,906,000	62,174,000	63,071,000
other liabilities	5,372,000	5,521,000	6,984,000	7,492,000	7,383,000	2,924,000	3,882,000	5,276,000	2,223,000	2,605,000	3,252,000	4,027,000	4,773,000	5,491,000	4,282,000	4,553,000	4,869,000	4,076,000	3,314,000	3,624,000	3,755,000	4,422,000	2,917,000	3,234,000	3,540,000	4,151,000	4,452,000	4,743,000	1,642,000	1,076,000	1,084,000	1,086,000	821,000	832,000	934,000	895,000	1,148,000	1,053,000	1,136,000	1,244,000	1,526,000	1,611,927	1,623,171	1,516,464	1,517,956	1,426,469	1,250,866	288,438	299,762	311,085	320,055	322,464	312,493	48,862
total liabilities	86,105,000	80,042,000	74,485,000	67,644,000	70,808,000	62,883,000	62,143,000	65,950,000	96,330,000	95,198,000	96,550,000	93,611,000	96,924,000	99,824,000	89,776,000	89,383,000	95,353,000	93,837,000	101,790,000	106,834,000	110,614,000	109,346,000	128,052,000	128,570,000	132,768,000	139,692,000	145,626,000	69,090,000	73,189,000	36,235,000	52,595,000	59,455,000	60,263,000	58,388,000	55,450,000	62,977,000	27,925,000	25,405,000	20,597,000	19,704,000	19,930,000	16,061,156	11,535,954	11,110,382	11,125,823	9,757,863	7,391,545	6,258,999	15,175,306	14,352,735	11,803,377	14,363,512	15,199,627	11,699,467	11,356,879	11,035,847	1,251,717	1,143,645	1,261,289	928,050	4,826,707	3,948,072
stockholders’ equity
common stock; .001 par value...	148,000				147,000				146,000				114,000				113,000				113,000	113,000	113,000	113,000		113,000	113,000	113,000		112,000	112,000	111,000		110,000	110,000	109,000		109,000	109,000	109,000		107,834	106,165	105,843	104,426	97,686	96,356	95,824	88,423	86,792	81,052	78,139	74,307	74,307	73,697	71,251	64,382	61,771	61,771	58,550	42,185	37,340	37,340	37,340	37,282	37,282	36,864
additional paid-in capital	299,081,000	296,670,000	291,096,000	286,864,000	284,219,000	279,558,000	274,685,000	280,000,000	276,249,000	188,369,000	182,907,000	178,829,000	173,804,000	171,865,000	169,352,000	165,490,000	165,695,000	162,003,000	158,720,000	156,733,000	158,610,000	158,318,000	151,625,000	149,765,000	147,231,000	143,647,000	136,298,000	166,296,000	164,744,000	163,446,000	161,883,000	153,735,000	161,261,000	159,940,000	156,457,000	151,659,000	163,133,000	156,074,000	156,401,000	158,401,000	162,433,000	157,893,595	154,078,653	150,874,988	147,284,219	107,834,381	104,881,706	102,826,481	89,627,601	87,199,392	79,471,324	75,558,539	73,868,604	71,247,000	70,555,255	67,513,409	57,888,506	54,767,409	54,434,441	50,924,762	40,697,152	35,084,069	34,230,824	33,409,193	33,233,660	32,456,207	32,226,983
accumulated deficit	-42,681,000	-57,872,000	-74,620,000	-84,236,000	-91,259,000	-98,697,000	-106,792,000	-124,417,000	-133,678,000	-187,155,000	-195,689,000	-196,889,000	-191,906,000	-191,492,000	-183,066,000	-172,198,000	-161,709,000	-163,924,000	-161,585,000	-159,806,000	-151,424,000	-134,844,000	-115,427,000	-106,961,000	-102,140,000	-94,664,000	-107,043,000	-89,833,000	-76,560,000		-13,759,000	-21,828,000	-26,155,000	-31,637,000	-34,958,000	-36,933,000	-38,129,000	-51,507,000	-58,058,000	-63,488,000	-67,575,000	-71,408,101	-75,107,806	-74,717,647		-72,368,637	-72,061,519	-71,304,130	-69,683,722	-68,078,438	-63,859,067	-63,114,998	-62,021,346	-59,444,151	-57,678,427	-55,174,922	-51,827,360
total stockholders’ equity	256,548,000				193,107,000				142,717,000								82,000								34,398,000			38,352,000	49,655,000																											12,384,738	6,100,528	5,703,477	8,224,951	7,408,620	2,518,279	1,411,928	2,156,226	4,206,579	6,876,685	11,307,763	14,230,003
total liabilities and stockholders’ equity	342,653,000	318,988,000	291,109,000	270,420,000	263,915,000	243,891,000	230,183,000	221,681,000																	167,166,000			107,442,000	122,844,000																											23,420,585	7,352,245	6,847,122	9,486,240	8,336,670	7,344,986	9,121,250	7,616,813	8,633,518	10,410,847	12,149,661	15,178,481
prepaid expenses		4,248,000	4,863,000	5,351,000	5,018,000	2,907,000	4,030,000	6,095,000	5,624,000	2,954,000	3,683,000	8,824,000	8,646,000	4,679,000	4,085,000	6,136,000	6,146,000	2,078,000	3,350,000	4,695,000	5,605,000	1,492,000	2,850,000	5,239,000	6,669,000	1,895,000	2,548,000	4,620,000	6,673,000	6,662,000	8,218,000	6,878,000	5,894,000												1,337,408
right of use asset		4,668,000	4,987,000	5,299,000		2,843,000	3,175,000	3,499,000		2,441,000	2,742,000	3,066,000	3,400,000	3,728,000	4,049,000	4,364,000	4,696,000	2,899,000	3,144,000	3,567,000	3,623,000	4,031,000	2,911,000	3,158,000	3,397,000	3,630,000	3,852,000	4,075,000
deferred tax asset		21,647,000	27,397,000	27,685,000		30,636,000	33,441,000	38,747,000																						17,671,000	10,144,000	9,530,000	9,114,000	7,019,000	7,077,000	4,940,000	14,838,000
stockholders' equity
common stock; 0.001 par value...		148,000	148,000	148,000		147,000	147,000	148,000		116,000	116,000	115,000		114,000	114,000	114,000		113,000	113,000	113,000					113,000				113,000				110,000				109,000				108,000
total stockholders' equity		238,946,000	216,624,000	202,776,000		181,008,000	168,040,000	155,731,000		1,330,000												12,870,000	22,860,000	30,339,000		39,575,000	24,684,000			142,472,000	147,270,000	129,036,000	133,000,000	123,277,000	121,605,000	114,243,000	107,988,000	100,522,000	93,240,000	86,401,000	89,329,000	81,256,251	74,488,679	76,238,184	73,568,070	35,538,430	32,891,543	31,593,175	20,007,302	19,182,746	15,668,309	12,496,680	11,896,565	11,852,156	12,925,525
right of use assets					5,606,000				2,132,000
current portion of profit share payments					1,421,000	2,860,000	2,196,000
current liabilities of discontinued operations							217,000	344,000	1,352,000
commitments and contingencies
current assets of discontinued operations
noncurrent assets of discontinued operations
liabilities, convertible preferred stock, and stockholders’ equity
convertible preferred stock series b; .001 par value...													92,494,000				92,494,000				91,568,000	91,108,000
total liabilities, convertible preferred stock, and stockholders’ equity									239,047,000	189,022,000							187,929,000					213,324,000
cash										81,164,000
convertible preferred stock series b; 0.001 par value...										92,494,000	92,494,000	92,494,000		92,494,000	92,494,000	92,494,000		92,494,000	92,494,000	92,030,000
preferred stock series a; 0.001 par value...
liabilities, convertible preferred stock, and stockholders’ deficit
stockholders' deficit
total stockholders' deficit											-12,666,000	-17,946,000						-5,808,000	-7,137,000	-8,051,000
total liabilities, convertible preferred stock, and stockholders’ deficit											176,378,000	168,159,000						180,523,000	187,147,000	190,813,000
treasury stock												-1,000		-7,000	-3,000	-840,000	-4,017,000	-4,000,000	-4,385,000	-5,091,000	-7,449,000	-10,717,000	-13,451,000	-12,578,000	-10,806,000	-9,521,000	-4,684,000	-38,224,000	-38,642,000	-24,784,000	-966,000	-2,982,000	-2,216,000	-5,136,000	-4,000	-592,000	-17,125,000	-4,154,000	-5,212,000	-8,621,000	-5,637,000	-5,337,077	-4,588,333	-25,000		-25,000	-25,000	-25,000	-25,000	-25,000	-25,000	-25,000	-25,000	-25,000	-25,000	-25,000	-25,000	-25,000	-25,000	-25,000	-25,000
income tax receivable													704,000	756,000	809,000	680,000	743,000	625,000	10,138,000	9,991,000	10,045,000	10,853,000	10,700,000	10,729,000	18,000	843,000	534,000	466,000	454,000
liabilities, convertible preferred stock, and stockholders’ (deficit) equity
stockholders’ (deficit) equity:
preferred stock series a; .001 par value...
total stockholders’ (deficit) equity													-17,988,000								-150,000
total liabilities, convertible preferred stock, and stockholders’ (deficit) equity													171,430,000	172,798,000	168,667,000	174,443,000					202,032,000
net sales													267,841,000	67,689,000	66,883,000	58,894,000					248,234,000
cost of sales													48,316,000	12,188,000	11,823,000	9,936,000					39,330,000
gross profit													219,525,000	55,501,000	55,060,000	48,958,000					208,904,000
operating expenses:
selling, general and administrative													208,789,000	53,475,000	55,793,000	49,570,000					181,022,000
research and development													22,829,000	5,953,000	5,512,000	5,964,000					11,715,000
investigation, restatement and related													12,177,000	3,001,000	3,218,000	2,552,000					59,465,000
amortization of intangible assets													701,000	175,000	173,000	172,000					1,073,000
impairment of intangible assets																					1,027,000
operating income													-24,971,000	-7,103,000	-9,636,000	-9,300,000					-45,398,000
other income													-4,000								-3,000
interest expense													-5,016,000	-1,270,000	-1,170,000	-1,126,000
loss on extinguishment of debt																					-8,201,000
income before income tax provision													-29,991,000	-8,373,000	-10,806,000	-10,426,000					-61,543,000
income tax provision benefit													-206,000		-62,000						12,259,000
net income													-30,197,000	-8,426,000	-10,868,000	-10,489,000					-49,284,000
net income available to common stockholders													-36,777,000	-10,096,000	-12,496,000						-83,328,000
net income per common share - basic													-330	-90	-110	-110					-770
net income per common share - diluted													-330	-90	-110	-110					-770
weighted-average common shares outstanding - basic													112,909,266,000	113,448,251,000	112,867,912,000	111,615,839,000					108,257,112,000
weighted-average common shares outstanding - diluted													112,909,266,000	113,448,251,000	112,867,912,000	111,615,839,000					108,257,112,000
stockholders' (deficit) equity
total stockholders' (deficit) equity														-19,520,000	-13,603,000	-7,434,000
income tax provision expense														-53,000		-63,000
net income available to common shareholders																-12,075,000
interest income																					-7,941,000
liabilities and stockholders' equity
stockholders' equity:
preferred stock; .001 par value...
total liabilities and stockholders' equity																							150,912,000	158,909,000		179,267,000	170,310,000			178,707,000	199,865,000	188,491,000	193,263,000	181,665,000	177,055,000	177,220,000	135,913,000	125,927,000	113,837,000	106,105,000	109,259,000	97,317,407	86,024,633	87,348,566	84,693,893	45,296,293	40,283,088	37,852,174	35,182,608	33,535,481	27,471,686	26,860,192	27,096,192	23,551,623	24,282,404
stockholders’ equity:
preferred stock; 0.001 par value...
current liabilities
intangible assets, net of accumulated amortization																														10,377,000	22,289,000	22,788,000	23,268,000	27,249,000	27,693,000	33,710,000	10,763,000	10,740,000	10,781,000	10,813,000	10,845,000	10,960,300	11,004,073	11,115,188	11,178,573
current portion of earn out liability																															17,574,000	8,740,000	8,740,000	9,642,000	9,642,000
income taxes																														2,329,000	-822,000	7,839,000	5,768,000
earn out liability																																8,769,000	8,710,000	15,978,000	15,978,000	33,240,000
accumulated earnings																														3,698,000
deferred financing costs and other assets																															264,000	309,000	354,000	399,000	444,000	477,000	487,000
short term investments																																				2,500,000	3,000,000	6,500,000	7,250,000	6,000,000	5,750,000
prepaid expenses and other current assets																																		6,212,000	5,970,000	5,774,000	3,609,000	2,741,000	2,647,000	2,341,000	1,540,000	1,968,290	2,325,535	2,278,996		1,544,369	1,351,948	1,186,417	657,961	546,715	292,223	377,495	164,664	254,694	234,192	248,712	90,946	123,669	121,981	171,854	180,254	49,082	82,953	8,321	58,835	67,577	189,253
investments																																								2,500,000	3,250,000
earn-out liability payable in mimedx common stock																																																	5,792,330
convertible senior secured promissory notes																																																	4,012,442
intangible assets, net of accumulated amortization of 5,638,565 and 4,848,756, respectively																																														11,648,506
deposits and other long term assets																																																319,545	70,000	180,428	204,803	209,595	214,342	167,257	119,082	119,083	102,500	102,500
intangible assets, net of accumulated amortization of 5,378,990 and 4,848,756, respectively																																															11,724,210
intangible assets, net of accumulated amortization of 5,111,352 and 4,848,756, respectively																																																11,649,153
intangible assets, net of accumulated amortization of 4,848,756 and 3,468,515, respectively																																																	11,911,749
current portion of line of credit with related party
current portion of long term convertible debt related to acquisition
commitments and contingency
intangible assets, net of accumulated amortization and impairments of 6,384,656 and 3,468,515, respectively																																																		12,174,344
accounts payable and accrued expenses																																																		3,750,350	1,902,349	1,825,765	2,300,638	1,877,402	1,618,907	1,686,272	848,285	1,143,645		928,050	932,741	1,106,925	1,699,337	1,190,689	1,532,054	841,898	948,478
convertible line of credit with related party, net of unamortized discount of 217,678 and 46,746, respectively, plus accrued interest of 91,521 and 42,726, respectively																																																		1,173,846
convertible debt related to acquisition, net of unamortized discount of 170,509, plus accrued interest of 49,315
current portion of earn-out liability payable in mimedx common stock																																																		5,545,280	4,225,280	3,185,223	3,185,223	3,850,000
earn-out liability payable in mimedx common stock, net of current portion																																																				4,225,280	4,225,280	3,554,700
convertible senior secured promissory notes, net of unamortized discount of 1,569,592 and 2,263,145, respectively, plus accrued interest of 63,133 and 7,732, respectively																																																		3,493,540
intangible assets, net of accumulated amortization of 4,136,469 and 3,468,515, respectively																																																			14,422,531
convertible line of credit with related party, net of unamortized discount of 398,899 and 46,746, respectively, plus accrued interest of 75,137 and 42,726, respectively																																																			976,238
convertible debt related to acquisition, net of unamortized discount of 3,821 and 170,509, respectively, plus accrued interest of 69,808 and 49,315, respectively																																																			1,065,987
convertible senior secured promissory notes, net of unamortized discount of 1,818,446 and 2,263,145, respectively, plus accrued interest of 61,933 and 7,732, respectively																																																			3,243,487
intangible assets, net of accumulated amortization of 3,802,492 and 3,468,515, respectively																																																				14,756,508
deferred rent current																																																				6,620	6,620	6,620		6,620
convertible line of credit with related party, net of unamortized discount of 549,779 and 46,746, respectively, plus accrued interest of 58,931 and 42,726, respectively																																																				809,152
convertible debt related to acquisition, net of unamortized discount of 90,156 and 170,509, respectively, plus accrued interest of 59,836 and 49,315, respectively																																																				969,680
convertible senior secured promissory notes, net of unamortized discount of 2,049,190 and 2,263,145, respectively, plus accrued interest of 68,518 and 7,732, respectively																																																				3,019,328
intangible assets, net of accumulated amortization of 3,468,515and 2,132,606, respectively																																																					15,090,485
convertible notes, plus accrued interest of 3,432
convertible line of credit with related party, net of unamortized discount of 46,746 plus accrued interest of 42,726																																																					1,295,980
convertible debt related to acquisition, net of unamortized discount of 170,509 plus accrued interest of 49,315																																																					1,128,806
convertible senior secured promissory notes, net of unamortized discount of 2,263,145 plus accrued interest of 7,732																																																					2,744,587
intangible assets, net of accumulated amortization of 3,134,538 and 2,132,606, respectively																																																						15,424,462
notes payable, plus accrued interest of 268																																																						37,398
customer deposits																																																						14,725	43,125
current portion of convertible debt, net of unamortized discount of 245,296 plus accrued interest of 36,712																																																						1,041,416
convertible line of credit with related party, net of unamortized discount of 52,698 plus accrued interest of 21,042																																																						1,268,344
intangible assets, net of accumulated amortization of 2,800,561and 2,132,606, respectively																																																							15,758,439
short-term convertible notes, plus accrued interest of 3,432																																																									403,432
short-term notes payable, plus accrued interest of 97																																																							45,540
deferred rent																																																							6,620
earn-out liability, payable in mimedx stock																																																							3,850,000
convertible debt, plus accrued interest of 24,110																																																							959,209
convertible line of credit with related party, plus accrued																																																							1,240,877
interest of 9,959 and amortized discount of 10,918
notes payable, plus accrued interest of 301																																																							7,704
other long term liabilities																																																							30,197	22,285
intangible assets, net of accumulated amortization of 2,466,583 and 2,132,606, respectively																																																								16,092,417
line of credit with a related party																																																								800,000
short-term notes payable, plus accrued interest of 146																																																								205,140
accrued contingent consideration																																																								7,404,700
long-term convertible debt, plus accrued interest of 11,644																																																								897,061
long-term notes payable, plus accrued interest of 362																																																								13,769
intangible assets, net of accumulated amortization of 2,132,606 and 1,464,674, respectively																																																									3,929,394
deferred financing costs																																																													209,971	226,771
long-term convertible debt, face value 3,472,000, less unamortized discount of 550,748 and including accrued interest of 69,604
intangible assets, net of accumulated amortization of 1,965,623 and 1,464,674, respectively																																																										4,096,377
long term convertible debt, face value 3,472,000, less unamortized discount of 550,748 and including accrued interest of 69,604
deficit accumulated during the development stage																																																										-49,100,703	-46,246,261	-43,549,692	-38,196,058	-33,709,481	-32,111,938	-29,239,954	-26,195,899	-21,185,726	-18,033,844
trade accounts receivable																																																											380,565	115,655
intangible assets, net of accumulated amortization of 1,798,640 and 1,464,674																																																											4,263,360
deposits and other long term receivables																																																											92,500	111,180
accounts payable & accrued expenses																																																											1,261,289
intangible assets, net of accumulated amortization of 1,631,657																																																												4,430,343
intangible assets, net of accumulated amortization of 1,324,070																																																													4,782,927
deposits																																																													149,202	149,202	149,202	149,302	149,302	150,114	146,433
hybrid debt instrument																																																													369,055
warrant derivative liability																																																													609,666
long term convertible debt, face value 3,472,000 less unamortized discount of 600,319 and including accrued interest of 43,564																																																													2,915,245
common stock with registration rights,1,905,000 shares issued and outstanding march
intangible assets, net of accumulated amortization of 1,157,364																																																														4,949,633
long term convertible debt, face value 3,472,000, less unamortized discount of 648,377 and including accrued interest of 17,524																																																														2,841,147
common stock with registration rights,1,905,000 shares issued and outstanding																																																														3,761,250
common stock with registration rights, 1,905,000 shares issued and outstanding																																																															3,761,250
intangible assets, net of accumulated amortization of 823,960																																																																5,283,041
common stock with registration rights, 210,000 shares issued and outstanding																																																																945,000
redeemable common stock, 487,500 shares issued and outstanding																																																																2,291,250	2,002,108
intangible assets, net of accumulated amortization of 657,256																																																																	5,449,745
stock subscriptions receivable																																																																	-198,358
intangible assets, net of accumulated amortization of 490,552																																																																		5,616,449
due from related parties
investment, related party
deferred interest income
due to related party
convertible preferred stock series a; .0001 par value...
note receivable, related party

Cashflow Statements:

Quarterly

Annual

Unit: USD	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-11-22	2010-09-30	2010-06-30	2010-03-31	2009-09-30	2009-06-30	2009-03-31	2008-09-30	2008-06-30

cash flows from operating activities:
net income from continuing operations	15,191,000	16,748,000	9,616,000	7,023,000	7,438,000	7,878,000	17,621,000	9,061,000
adjustments to reconcile net income from continuing operations to net cash flows from operating activities from continuing operations:
share-based compensation	2,463,000	4,919,000	4,752,000	4,262,000	4,693,000	3,809,000	4,091,000	4,340,000	4,166,000	4,388,000	4,060,000	4,345,000	1,868,000	2,372,000	4,428,000	3,998,000	3,642,000	3,811,000	4,060,000	3,244,000	3,905,000	3,669,000	4,434,000	3,349,000	2,865,000	2,686,000	3,499,000	3,014,000	-464,000	5,306,000	5,255,000	4,671,000	3,992,000	4,702,000	4,509,000	4,615,000	4,332,000	4,378,000	4,253,000	3,933,000	3,292,322	3,021,962	2,766,352	2,372,364	1,854,171	1,667,766	1,502,447	984,792
depreciation and amortization	3,220,000	5,290,000	3,168,000	3,203,000
deferred income taxes	2,051,000	5,751,000	287,000	621,000
credit loss expense	3,366,000	2,056,000	351,000	742,000
non-cash lease expenses	325,000	318,000	312,000	307,000	338,000	331,000	324,000	317,000	309,000	301,000	324,000	334,000		321,000	315,000	295,000		244,000	243,000	237,000		216,000	247,000	239,000			223,000	269,000
shares received in settlement of litigation
loss on extinguishment of debt					0	0	0	1,401,000													0
other	98,000	249,000			682,000	-77,000
increase in cash resulting from changes in:
accounts receivable	-887,000	-11,014,000	-7,290,000	-7,203,000	-2,253,000	-953,000	3,998,000	-3,344,000	-5,578,000	-489,000	-4,619,000	-1,551,000	-2,255,000	-3,596,000	-2,378,000	2,679,000	-3,817,000	707,000	-1,823,000	3,000	-1,765,000	-3,327,000	1,601,000	395,000						-1,248,000	6,108,000	305,000	-3,725,000	-8,565,000	-980,000	1,874,000	-6,977,000	-7,330,000	-8,447,000	-4,329,000	-3,367,364	-2,804,894	-1,533,035	-2,873,707	-2,386,312	-1,944,650	-1,940,371	-2,167,942	-1,483,437	-2,223,791	-1,092,781	-961,633	-390,354	-259,058	-709,409	150,365	-115,655	149,834	-264,910	-115,655
inventory	1,162,000	-1,612,000	-820,000	-263,000	440,000	807,000	-663,000	-2,941,000	-1,953,000	-2,252,000	-2,159,000	-1,474,000	792,000	-593,000	-212,000	-1,781,000	-193,000	-1,059,000	1,445,000	-1,221,000	491,000	-505,000	-1,100,000	-143,000	2,930,000	2,918,000	1,476,000	-442,000	-10,257,000	1,110,000	939,000	1,689,000	762,000	-1,354,000	-1,981,000	-264,000	-1,807,000	-1,794,000	389,000	885,000	-394,086	-509,399	-590,197	241,682	652,286	-312,778	-263,945	-933,555	-1,220,449	-840,396	-166,423	-82,914	-103,463	-47,222	8,726	-111,983	-37,356	-22,493	-27,052	-37,356
other assets	-3,117,000	-3,440,000	-1,562,000	-699,000	-437,000	943,000	-463,000	-1,001,000	511,000	798,000	-804,000	1,030,000	-46,000	0	11,000	-298,000	-1,315,000	603,000	1,068,000	319,000	-1,752,000			812,000					3,964,000					101,000	-473,000	209,000		0	0	-26,000					0	0	319,545	-249,545	77,444				-32,201				63,021	-10,000	33,681	63,021
accounts payable	-1,586,000	2,913,000	-668,000	1,460,000	713,000	-1,045,000	-1,361,000	283,000	460,000	453,000	893,000	-1,023,000	-37,000	648,000	-14,000	456,000	502,000	-3,622,000	3,730,000	-936,000	-162,000	-2,897,000	2,190,000	1,046,000	-727,000	-1,372,000	101,000	-4,173,000	6,107,000	244,000	613,000	-379,000	276,000	1,656,000	-1,332,000	-4,265,000	-611,000	1,687,000	271,000	1,789,000	931,731	400,173	-173,126	128,222	254,653	368,067	781,004	-194,977
accrued compensation	3,415,000	6,362,000	3,282,000	-4,073,000	3,496,000	4,109,000	-269,000	-4,440,000	318,000	1,856,000	3,002,000	-3,347,000	-2,239,000	6,811,000	178,000	-6,494,000	3,043,000	-705,000	5,104,000	-2,314,000	316,000	-2,257,000	3,668,000	-4,186,000	226,000	1,866,000	3,687,000	-7,501,000	-790,000	519,000	3,117,000	-763,000	1,554,000	566,000	851,000	-5,640,000	2,037,000	3,336,000	941,000	-2,803,000	2,075,566	3,293,844	740,806	-175,216	1,028,431	1,585,671	-544,060	765,532
accrued expenses	-1,441,000	284,000	3,601,000	-73,000	142,000	-1,682,000	229,000	522,000	-419,000	-2,507,000	-992,000	2,210,000	38,000	984,000	190,000	550,000	-4,429,000	-3,016,000	-13,268,000	-484,000	6,581,000	7,274,000	-9,264,000	-2,845,000	-5,653,000	-5,379,000	7,080,000	3,895,000	18,302,000	605,000	-1,891,000	-942,000	4,277,000	-324,000	1,851,000	493,000	548,000	371,000	110,000	1,111,000	513,977	852,489	-231,540	-36,926	-66,581	334,243	-151,569	236,788
other liabilities	1,466,000	-110,000	-1,226,000	159,000	437,000	129,000	-1,241,000	-195,000	544,000	-467,000	-176,000	-398,000	-867,000	1,408,000	-139,000	-364,000	-319,000	-326,000	-337,000	-177,000	-878,000	-231,000	-1,318,000	709,000	-892,000	-5,000	-1,155,000	-665,000	1,958,000	-142,000	-34,000	-618,000	-1,816,000	1,221,000	775,000	543,000	576,000	-501,000	-363,000	-223,000	406,480	92,863	116,849	101,808	-161,271	85,940	57,686	-11,324	-11,323	-9,286	-2,093	9,971	26,208	-66,952	51,039	6,088
net cash flows from operating activities of continuing operations	24,956,000	29,329,000	14,419,000	5,299,000
net cash flows from operating activities of discontinued operations								-807,000
net cash flows from operating activities	24,956,000	29,329,000	14,419,000	5,299,000	18,782,000	19,624,000	21,814,000	5,978,000	10,257,000	12,791,000	7,775,000	-4,048,000	-5,624,000	959,000	-3,005,000	-10,223,000	-3,232,000	6,330,000	1,599,000	-6,679,000	-10,267,000	-4,618,000			-23,122,000	-3,160,000	2,130,000	-15,260,000	-6,278,000	17,951,000	13,483,000	10,640,000	16,680,000	2,845,000	7,280,000	-977,000	4,356,000	7,308,000	2,933,000	4,210,000	8,284,508	8,949,243	1,179,220	-1,610,971	839,186	1,728,885	-755,362	-2,098,186	-923,718	-862,302	-310,872	-1,287,939	-1,655,688	-1,089,563	-2,129,676	-1,789,844	-1,897,252	-2,270,896	-2,003,308	-1,897,252	-1,908,035	-1,750,103	-1,332,373	-2,431,932	-2,643,150
cash flows from investing activities:
cash paid for acquisitions	0	-3,064,000
purchases of equipment	-285,000	-192,000	-179,000	-377,000	-263,000	-171,000	-105,000	-1,144,000	-427,000	-628,000	-299,000	-633,000		-349,000	-380,000	-118,000		-547,000	-405,000	-1,941,000		-652,000	-410,000	-1,011,000		-156,000	-251,000	-648,000		-1,304,000	-1,771,000	-923,000	-968,000	-1,546,000	-1,747,000	-2,008,000	-1,651,000	-1,663,000	-1,166,000	-1,347,000	-727,739	-684,910	-679,583	-465,768	-328,110	-955,477	-979,396	-73,534	-181,067	-163,366	-191,704	-46,794	-68,191	-274,473
other investments	-89,000
net cash flows from investing activities	-335,000	-5,258,000	-887,000	-406,000	-2,767,000	113,000	-905,000	-6,024,000	-481,000	-649,000	-348,000	-677,000	-1,709,000	-374,000	-429,000	-148,000	-314,000	-580,000	-422,000	-2,079,000	-2,273,000	-710,000			-793,000	2,060,000	-330,000	-433,000	-5,078,000	-1,394,000	-1,779,000	-969,000	-1,295,000	-1,734,000	573,000	-9,286,000	1,592,000	-1,105,000	-117,000	-1,048,000	-9,844,644	-873,215	-800,427	-633,714	-490,441	-1,139,348	-1,322,091	-73,534	-181,067	-163,366	-191,704	-46,794	181,809	-274,473	-181,500	-428,344	-15,655	-28,816	-104,712	-15,655	-2,080	-8,285	-22,567	-70,937	-231,353
cash flows from financing activities:
stock repurchased for tax withholdings on vesting of restricted stock	-51,000	-83,000	-526,000	-2,458,000	-30,000	-110,000							1,000	0	0	-1,191,000	0	-188,000	-1,347,000	-3,216,000	75,000	-79,000	-792,000	-1,538,000
cash paid for profit share payment	-282,000	-524,000
proceeds from citizens revolving credit facility					0	0	0	30,000,000
proceeds from citizens term loan
prepayment premium on previous term loan
deferred financing cost					0	0	0	-1,101,000														-2,759,000
repayment of previous term loan
repayment of citizens revolving credit facility					0	0	0	-30,000,000
principal payments on citizens term loan facility					-250,000	-250,000	-250,000	-250,000
proceeds from exercise of stock options					-1,000	388,000	244,000	766,000	591,000	386,000			77,000	137,000	271,000	166,000	33,000	45,000	444,000	915,000	41,000	72,000	0	298,000	0	0			-8,035,000	2,398,000	7,327,000	1,865,000	946,000	532,000	878,000	1,138,000	1,164,000	724,000	1,465,000	1,276,000	972,910	614,383	437,635	445,072	464,838	973,739	310,310	232,531	167,634	569,739	144,295	171,000	0	295,750			101,875	0	751	101,875
repurchase of series b preferred shares
net cash flows from financing activities	-583,000	-857,000	-1,094,000	-2,878,000	-400,000	27,000	-359,000	-33,467,000	-8,940,000			-4,000	66,000	130,000	260,000	-1,036,000	22,000	-150,000	-916,000	-2,308,000	-1,243,000	66,734,000			-1,138,000	-1,707,000	66,748,000	-1,044,000	26,867,000	-27,568,000	4,905,000	-13,138,000	668,000	-6,576,000	833,000	-3,106,000	-18,535,000	-3,731,000	-2,911,000	-11,048,000	888,884	-68,262	-4,153,115	1,186,493	37,667,250	1,278,636	545,929	1,142,342	238,044	5,992,200	136,004	243,673	4,949,013	386,878	2,904,993	1,897,799	886,875	0	3,208,720	886,875	295,000	3,344,460	525,000
net change in cash	24,038,000	23,214,000	12,438,000	2,015,000	15,615,000	19,764,000	20,550,000	-33,513,000		12,512,000	7,431,000	-4,729,000	-7,267,000	715,000	-3,174,000	-11,407,000	-3,524,000	5,600,000	261,000	-11,066,000	-13,783,000	61,406,000	-5,336,000	-15,544,000	-25,053,000	-2,807,000	68,548,000	-16,737,000	15,511,000	-11,011,000	16,609,000	-3,467,000	16,053,000	-5,465,000	8,686,000	-13,369,000	-12,587,000	2,472,000	-95,000	-7,886,000	-671,252	8,007,766	-3,774,322	-1,058,192	38,015,995	1,868,173	-1,531,524	-1,029,378	-866,741	4,966,532	-366,572	-1,091,060	3,475,134	-977,158	593,817	-320,389	-1,026,032	-2,299,712	1,100,700	-1,026,032	-1,615,115	1,586,072		-1,527,869	-2,874,503
cash and cash equivalents, beginning of period	0	0	0	104,416,000	0	0	0	82,000,000	0	0	0	65,950,000		0	0	87,083,000		0	0	95,812,000		0	0	69,069,000		0	0	45,118,000		0	0	34,391,000	0	0	0	28,486,000	0	0	0	46,582,000	249	0	0	44,077,751	0	0	0	6,754,485
cash and cash equivalents, end of period	24,038,000	23,214,000	12,438,000	106,431,000	15,615,000	19,764,000	20,550,000	48,487,000	836,000	12,512,000	7,431,000	61,221,000		715,000	-3,174,000	75,676,000		5,600,000	261,000	84,746,000		61,406,000	-5,336,000	53,525,000		-2,807,000	68,548,000	28,381,000		-11,011,000	16,609,000	30,924,000	16,053,000	-5,465,000	8,686,000	15,117,000	-12,587,000	2,472,000	-95,000	38,696,000	-671,003	8,007,766	-3,774,322	43,019,559	38,015,995	1,868,173	-1,531,524	5,725,107
prepaid expenses		615,000	488,000	-333,000	-2,111,000	1,123,000	2,065,000	-471,000	-4,001,000	886,000	3,010,000	-178,000	-3,967,000	-594,000	2,050,000	11,000	-4,069,000	1,273,000	1,344,000	910,000	-4,113,000	1,358,000	2,389,000	1,430,000	-4,774,000	653,000	2,072,000	2,053,000	-3,756,000	1,532,000	-1,340,000	-984,000													206,961	-192,421	-165,531	-555,692
patent application costs		-2,000	-8,000	-29,000		284,000	-434,000	120,000	-54,000	-21,000	-49,000	-44,000	-42,000	-25,000	-49,000	-54,000	11,000	-63,000	-47,000	-153,000	-118,000	-58,000	-76,000	-75,000	-96,000	-117,000	-79,000	-174,000	-465,000	-90,000	-8,000	-46,000	-327,000	-188,000	-180,000	-147,000	-257,000	-192,000	-201,000	-201,000	-116,905	-188,305	-120,844	-167,946	-162,331	-183,871
principal payment on citizens term loan facility		-250,000	-250,000	-250,000
proceeds from citizens term loan facility					0	0	0	19,783,000
principal payments on finance lease						-1,000	-4,000	-13,000		-16,000	-16,000	-4,000		-7,000	-11,000	-11,000		-7,000	-13,000	-7,000
prepayment premium on hayfin term loan					0	0	0	-500,000
repayment of hayfin term loan					0	0	0	-50,000,000
amortization of deferred financing costs				135,000				69,000	132,000	128,000	124,000	121,000		119,000	117,000	112,000		110,000	418,000	415,000		370,000							2,000	45,000	45,000	45,000	45,000	45,000	42,000	49,000
accretion of asset retirement obligation				24,000				22,000	23,000	27,000	21,000	22,000	23,000	23,000	24,000	22,000	24,000	20,000	20,000	17,000
loss on fixed asset disposal								185,000					0	-2,000	0	-15,000	26,000	0	0	236,000							312,000	1,000																	28,441
change in the fair value of earnout liability				7,000
profit share payment				-170,000
adjustments to reconcile net income from continuing operations to net cash flows from operating activities of continuing operations:
deferred income tax provision
amortization of intangible assets					2,426,000	575,000	572,000	189,000	192,000	190,000	190,000	190,000	182,000	174,000	173,000	172,000	173,000	193,000	215,000	239,000	255,000	276,000	271,000	271,000	270,000	269,000	267,000	233,000	-417,000	418,000	507,000	526,000	238,000	632,000	447,000	810,000	234,000	234,000	232,000	233,000	232,632	232,078	231,959	231,331	264,162	259,575	267,638	262,596	262,595	449,692	333,977	333,977	333,977	333,977	333,977	333,977	166,983	166,983	166,983	166,983	166,706	166,704	166,704	166,704	166,704
depreciation					564,000	580,000	577,000	558,000	611,000	653,000	687,000	714,000	796,000	831,000	858,000	860,000	973,000	923,000	1,306,000	1,161,000	1,288,000	1,566,000	1,422,000	1,506,000	1,565,000	1,641,000	1,645,000	1,695,000	2,808,000	1,013,000	1,115,000	946,000	939,000	839,000	821,000	734,000	552,000	471,000	422,000	354,000	332,842	313,177	287,850	263,131	223,081	176,231	139,183	98,751	110,942	122,934	121,103	110,388	115,651	98,989	115,682	116,180	110,992	114,330	112,272	110,992	110,895	116,116	111,820	106,436	97,290
fair value of shares received in settlement of litigation						0
change in deferred income taxes						2,805,000	5,306,000	2,031,000																					34,098,000	-7,527,000	-614,000	-416,000
impairment of intangible assets																										0	0	1,258,000																					0
bad debt expense						-278,000	220,000	199,000	712,000	448,000	349,000	-60,000	3,000	426,000								382,000
net cash flows from operating activities from continuing operations						19,625,000	21,937,000	6,785,000
net cash flows from operating activities from discontinued operations						-1,000
consideration paid pursuant to tela apa						0	-366,000	-5,000,000
stock repurchased for tax withholdings on vesting of restricted stock units								-2,152,000
sales of equipment
cash paid for licensing agreement
principal payments from note receivable																	0	30,000	30,000	15,000					0			389,000
payments under finance lease obligations
net change in cash and cash equivalents
net income																									-7,476,000	12,379,000	-17,210,000	-13,273,000	-59,832,000	17,457,000	8,069,000	4,327,000	5,481,000	3,321,000	1,975,000	1,197,000	13,378,000	6,551,000	5,430,000	4,087,000	3,832,526	3,699,705	-390,159	-922,072	-1,426,938	-307,118	-757,389	-1,620,408									-3,142,085
adjustments to reconcile net income to net cash flows from operating activities:
impairment of clinical trial assets										-156,000
impairment of goodwill										0
gain on fixed asset disposal
proceeds from sale of equipment														0	0	24,000
net loss											1,200,000	-4,983,000	-414,000	-8,426,000	-10,868,000	-10,489,000	2,215,000	-2,339,000	-1,779,000	-8,382,000	-16,580,000	-19,417,000	-8,466,000	-4,821,000																									-1,605,284	-4,219,371	-744,069	-1,093,652	-2,577,195	-1,765,724	-2,503,505	-3,347,562		-2,854,442	-2,696,569	-3,142,085	-4,486,577	-1,597,543	-2,871,984	-3,586,350	-3,151,882
adjustments to reconcile net loss to net cash flows from operating activities:
adjustments to reconcile net loss to net cash from operating activities:
non cash lease expenses																									233,000
amortization of deferred financing costs and debt discount																								668,000
income taxes													52,000	53,000	-129,000	63,000	-118,000	9,513,000	-147,000	54,000	808,000									3,152,000	-8,661,000	2,071,000
purchases of property and equipment
proceeds from property and equipment sale
proceeds from sale of series b convertible preferred stock																					0
stock issuance costs																					-906,000
proceeds from term loans																					0
deferred financing costs																																	76,000	-45,000	-41,000	-20,000
repayment of term loans																					0
prepayment premium on early repayment of term loan																					0
cash and cash equivalents, beginning of year
cash and cash equivalents, end of year
effect of change in revenue recognition																									0
amortization of discount on notes receivable
stock repurchase under repurchase plan																																-12,666,000	0	-6,848,000	0	-3,530,000
payments under capital lease obligations																													19,000	-7,000	-5,000	-10,000	-81,000	-7,000	-4,000	-10,000		-28,000	-30,000	-29,000								-14,813
reserve for inventory obsolescence																						46,000
income tax receivable																							29,000	-10,711,000	825,000	-309,000	-68,000	-12,000
other current assets																										-1,988,000	85,000	-1,612,000			177,000	87,000
proceeds from term loan																									0	0
repayment of term loan																							-10,938,000	-937,000	-937,000
adjustments to reconcile net income to net cash from operating activities:
cash flows from operating activities																								-12,281,000
cash flows from investing activities																								-1,086,000
cash flows from financing activities																								-2,177,000
amortization of inventory fair value step-up																														50,000	78,000	75,000	14,000	247,000
change in fair value of earn-out consideration
intangible asset impairment
loss on divestiture of stability
increase in cash, net of effects of divestiture, resulting from changes in:
shares repurchased for tax withholdings on vesting of restricted stock																												-1,044,000
mimedx group, inc. and subsidiariesconsolidated statements of cash flows
shares repurchased under repurchase plan
loss of fixed asset disposal
proceeds from sale of property and equipment
payment under capital lease obligations
amortization of deferred financing costs and discount
principal payments on note receivable
share repurchase for tax withholdings on vesting of restricted stock																														-671,000
share repurchase under repurchase plan																														-29,288,000
increase in cash, net of effects of acquisition and divestiture, resulting from changes in:
stability acquisition
fixed maturity securities redemption																																	0	0	2,500,000	500,000		750,000	1,250,000	500,000
gain on divestiture
increase in cash, net of effects of acquisition, resulting from changes in:
purchase of stability inc., net of cash acquired																																	0	0	0	-7,631,000
stock repurchase for tax withholdings on vesting of restricted stock																																-2,327,000	-273,000	-208,000	0	-684,000
proceeds from exercise of warrants																																									244,375	93,875	0	774,750	627,759	312,500	243,000	924,624	75,524	5,601,901	965	322,673
prepaid expenses and other current assets																																		-242,000	285,000	-2,066,000		-95,000	-305,000	-801,000	427,882	357,245	-46,539	-941,588					-84,009	-254,492	85,272	-212,831	90,030	-20,502	14,517	-155,025	-35,576	-1,688	34,872	-35,576	-89,172	33,871	-74,632	8,742	121,676
amortization of inventory fair value step - up																																				734,000
amortization of debt discount and deferred financing costs																																													0	0	0	1,328,439	491,812	439,063	472,748	310,478	68,345	113,290	60,599	72,918	568,636	0	-69,026	568,636	98,228	37,966
prepaid expenses and other assets
accrued interest																																													0	0	0	-41,641	75,121	80,668	82,095	150,012	42,605	27,583	22,315	15,383
maturity (purchases) of fixed maturity securities
proceeds from public offering, net of expenses
stock repurchase																																					-19,211,000	-4,427,000	-4,346,000	-12,295,000	-299,923	-748,744
principal payments of equipment leases																																									-28,478	-27,776	-27,417	-33,329	-27,653	-7,603
change in fair value of earn-out liability																																																	247,050
purchases of fixed maturity securities
repayment of convertible debt related to acquisition																																																	0	-177,126	0	-250,000
repurchase of warrants																																																	0
cash paid for acquisition, net of cash acquired of 33,583
proceeds from grant
proceeds from senior secured promissory notes
proceeds from line of credit with related party
proceeds from sale of common stock and warrants and common stock with registration rights																																																					-13,001			1,212,175	785,000	0	0	785,000
repayment of line of credit																																																					0	0	0	-99,000
repayment of note payable
employee share-based compensation expense																																																	643,053	554,136	478,442	400,049	275,608	222,792	429,096	380,373	189,467	270,460	271,289	189,467	183,765	47,006	456,367	151,217	193,058
other share-based compensation expense																																																	139,999	115,333	106,773	100,936	66,060	62,946	114,648	107,560	9,667	62,508	32,887	9,667	77,616	31,165	365,264	31,163	36,584
increase in cash resulting from changes in
repayment of equipment lease																																																	-5,114	-1,746
cash, beginning of period																																																	0	0	0	4,112,326	0	0	0	1,340,922	2,653,537	0	0	2,653,537	0	34,828	0	0	6,749,609
cash, end of period																																																	-866,741	4,966,532	-366,572	3,021,266	3,475,134	-977,158	593,817	1,020,533	1,627,505	-2,299,712	1,100,700	1,627,505	-1,615,115	1,620,900	-829,940	-1,527,869	3,875,106
accounts payable and accrued expenses																																																		1,785,500	14,084	-352,720	423,238	258,492	-67,361	641,882	324,654	-117,643	402,265	324,654	-4,631	-20,550	508,648	690,156	-106,580
cash paid for acquisition, net of cash aquired of 33,583																																																					0
supplemental disclosure of cash flow information:
cash paid for interest																																																		3,303	3,000	2,435	10,614	2,009	-406	3,239
cash paid for income taxes
financing expense associated with warrants issued in connection with convertible promissory note
proceeds from reba grant
proceeds from note payable with related party																																																					0
proceeds from bridge loan
repayment of notes payable																																																					-37,986	-19,739	-15,556	-15,376
adjustments to reconcile net loss to net cash flows from operating activities, net of effects of acquisition:
increase in cash resulting from changes, net of effects of acquisition, in:
net proceeds from line of credit with related party
proceeds from sale of common stock and warrants
increase in cash resulting from changes in assets and liabilities, net of effects of acquisition:
purchase of equipment																																																								-111,927	-15,655	-28,816	-104,712	-15,655	-2,080	-8,285		-71,749	-227,672
cash paid in conjunction with acquisition, net of cash received of 33,583																																																								-316,417
proceeds from line of credit																																																								800,000
gain on settlement of payables																																																													-1,381	-564,838
loss on sale of assets
financing expense associated with issuance of common stock for waivers of registration rights
modifications of options and purchase of treasury stock
proceeds from sale of assets
cash paid in conjunction with sales of assets
proceeds from convertible debt offering																																																													0	3,472,000
proceeds from convertible promissory note
repayment of convertible promissory note
net proceeds from exercise of warrants																																																										0
offering costs paid in connection with convertible debt offering																																																													0	-127,540
adjustments to reconcile net income to net cash flows from operating activities, net of effects of acquisition:
(gain)/loss on sale of equipment
acquired in-process research and development
issuance of common stock for transaction fees
accrued interest on notes receivable, related party
change in fair value of investment, related party
deferred interest income
cash paid for intangible asset
cash received in acquisition of spinemedica corp.
cash paid for acquisition costs of spinemedica corp.
payments from (advances to) related party
proceeds from series a preferred stock
proceeds from series c preferred stock
offering costs paid in connection with series a preferred stock offering
balances, november 22, 2006
issuance of common stock at inception
common stock issued in connection with purchase of license agreement
issuance of note receivable, related party
sale of series a preferred stock																																																									11,212,800
accrued interest income
net income for the period
balances, march 31, 2007																																																									11,212,800
collection of stock subscription receivable
spinemedica corp. acquisition
sale of series c preferred stock
stock options issued in connection with purchase of intellectual property
exercise of stock options
alynx merger — recapitalization																																																									7,207,398
alynx merger — transaction costs
conversion of preferred stock																																																									-18,420,198
balances, march 31, 2008
provision for bad debts
loss on sale of equipment
advances to related party
net costs related to the acquisition of spinemedica corp.
supplemental disclosure of non-cash financing activity:
during the six months ended june 30, 2010 the company converted its outstanding convertible debt and accrued interest to equity by issuing 7,135,114 shares of common stock
payments for purchase of equipment
cash paid for security deposits																																																															100	812	-3,681
repayments of related party borrowing
supplemental disclosure of cash flow information
cash paid for:
interest
issuance of common stock for waivers of registration rights
derivative expense
proceeds from common stock sale
during the three months ended june 30, 2009, the company issued 315,520 warrants to purchase common stock, valued at 98,574 and recognized a beneficial conversion feature of 676,500 in conjunction with our convertible debt offering
payments on related party borrowing
proceeds from sale of redeemable common stock and warrants and common stock with registration rights
proceeds from sale of common stock and exercise of stock options
1.
proceeds from sale of warrants and redeembable common stock
proceeds from (repayments of) related party borrowing

MiMedx Group, Inc(NASDAQ:MDXG)

MiMedx Group, Inc
(NASDAQ:MDXG)